These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

375 related items for PubMed ID: 26605343

  • 1. A Humanized Anti-CD22-Onconase Antibody-Drug Conjugate Mediates Highly Potent Destruction of Targeted Tumor Cells.
    Weber T, Mavratzas A, Kiesgen S, Haase S, Bötticher B, Exner E, Mier W, Grosse-Hovest L, Jäger D, Arndt MA, Krauss J.
    J Immunol Res; 2015; 2015():561814. PubMed ID: 26605343
    [Abstract] [Full Text] [Related]

  • 2. A Novel Anti-CD22 Anthracycline-Based Antibody-Drug Conjugate (ADC) That Overcomes Resistance to Auristatin-Based ADCs.
    Yu SF, Zheng B, Go M, Lau J, Spencer S, Raab H, Soriano R, Jhunjhunwala S, Cohen R, Caruso M, Polakis P, Flygare J, Polson AG.
    Clin Cancer Res; 2015 Jul 15; 21(14):3298-306. PubMed ID: 25840969
    [Abstract] [Full Text] [Related]

  • 3. Anti-CD22 Onconase: preparation and characterization.
    Newton DL, Stockwin LH, Rybak SM.
    Methods Mol Biol; 2009 Jul 15; 525():425-43, xiv. PubMed ID: 19252847
    [Abstract] [Full Text] [Related]

  • 4. DCDT2980S, an anti-CD22-monomethyl auristatin E antibody-drug conjugate, is a potential treatment for non-Hodgkin lymphoma.
    Li D, Poon KA, Yu SF, Dere R, Go M, Lau J, Zheng B, Elkins K, Danilenko D, Kozak KR, Chan P, Chuh J, Shi X, Nazzal D, Fuh F, McBride J, Ramakrishnan V, de Tute R, Rawstron A, Jack AS, Deng R, Chu YW, Dornan D, Williams M, Ho W, Ebens A, Prabhu S, Polson AG.
    Mol Cancer Ther; 2013 Jul 15; 12(7):1255-65. PubMed ID: 23598530
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies.
    DiJoseph JF, Armellino DC, Boghaert ER, Khandke K, Dougher MM, Sridharan L, Kunz A, Hamann PR, Gorovits B, Udata C, Moran JK, Popplewell AG, Stephens S, Frost P, Damle NK.
    Blood; 2004 Mar 01; 103(5):1807-14. PubMed ID: 14615373
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Sortase Enzyme-Mediated Generation of Site-Specifically Conjugated Antibody Drug Conjugates with High In Vitro and In Vivo Potency.
    Beerli RR, Hell T, Merkel AS, Grawunder U.
    PLoS One; 2015 Mar 01; 10(7):e0131177. PubMed ID: 26132162
    [Abstract] [Full Text] [Related]

  • 9. Antibody-targeted chemotherapy of B-cell lymphoma using calicheamicin conjugated to murine or humanized antibody against CD22.
    DiJoseph JF, Popplewell A, Tickle S, Ladyman H, Lawson A, Kunz A, Khandke K, Armellino DC, Boghaert ER, Hamann P, Zinkewich-Peotti K, Stephens S, Weir N, Damle NK.
    Cancer Immunol Immunother; 2005 Jan 01; 54(1):11-24. PubMed ID: 15693135
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Epratuzumab-SN-38: a new antibody-drug conjugate for the therapy of hematologic malignancies.
    Sharkey RM, Govindan SV, Cardillo TM, Goldenberg DM.
    Mol Cancer Ther; 2012 Jan 01; 11(1):224-34. PubMed ID: 22039078
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Microscale screening of antibody libraries as maytansinoid antibody-drug conjugates.
    Catcott KC, McShea MA, Bialucha CU, Miller KL, Hicks SW, Saxena P, Gesner TG, Woldegiorgis M, Lewis ME, Bai C, Fleming MS, Ettenberg SA, Erickson HK, Yoder NC.
    MAbs; 2016 Jan 01; 8(3):513-23. PubMed ID: 26752675
    [Abstract] [Full Text] [Related]

  • 15. Production and characterization of a camelid single domain anti-CD22 antibody conjugated to DM1.
    Ziaei V, Ghassempour A, Davami F, Azarian B, Behdani M, Dabiri H, Habibi-Anbouhi M.
    Mol Cell Biochem; 2024 Mar 01; 479(3):579-590. PubMed ID: 37129769
    [Abstract] [Full Text] [Related]

  • 16. Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes.
    Pfeifer M, Zheng B, Erdmann T, Koeppen H, McCord R, Grau M, Staiger A, Chai A, Sandmann T, Madle H, Dörken B, Chu YW, Chen AI, Lebovic D, Salles GA, Czuczman MS, Palanca-Wessels MC, Press OW, Advani R, Morschhauser F, Cheson BD, Lenz P, Ott G, Polson AG, Mundt KE, Lenz G.
    Leukemia; 2015 Jul 01; 29(7):1578-86. PubMed ID: 25708834
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. MORAb-202, an Antibody-Drug Conjugate Utilizing Humanized Anti-human FRα Farletuzumab and the Microtubule-targeting Agent Eribulin, has Potent Antitumor Activity.
    Cheng X, Li J, Tanaka K, Majumder U, Milinichik AZ, Verdi AC, Maddage CJ, Rybinski KA, Fernando S, Fernando D, Kuc M, Furuuchi K, Fang F, Uenaka T, Grasso L, Albone EF.
    Mol Cancer Ther; 2018 Dec 01; 17(12):2665-2675. PubMed ID: 30262588
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. High treatment efficacy by dual targeting of Burkitt's lymphoma xenografted mice with a (177)Lu-based CD22-specific radioimmunoconjugate and rituximab.
    Weber T, Bötticher B, Mier W, Sauter M, Krämer S, Leotta K, Keller A, Schlegelmilch A, Grosse-Hovest L, Jäger D, Haberkorn U, Arndt MA, Krauss J.
    Eur J Nucl Med Mol Imaging; 2016 Mar 01; 43(3):489-98. PubMed ID: 26341366
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.